Recent Updates
Recently added Catalysts
UTHR Positive Sentiment

United Therapeutics Corporation Reports Third Quarter 2026 Financial Results

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: United Therapeutics reported third-quarter 2026 revenues of $832.5 million, a four percent increase from $799.5 million in the prior year period. The company stated it is entering a period of extraordinary growth. This expansion is driven by a portfolio of new therapies currently in development. These results reflect steady financial progress for the biopharma firm.

Market Sentiment Analysis

POSITIVE FACTORS

  • Total revenues increased by four percent year-over-year.
  • Revenues reached $832.5 million in Q3 2026.
  • Company is entering a period of extraordinary growth.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+27%
120-day peak, hindsight
Typical move
5.1%
average across 11 past catalysts
Lead asset
APD811
NDA/BLA · Pulmonary Arterial Hypertension

Full Press Release Details

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2026. Total revenues in the third quarter of 2026 increased by four percent year-over-year to $832.5 million, compared to $799.5 million in the third quarter of 2025. “United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies

Frequently Asked Questions

What were United Therapeutics' Q3 2026 revenues?

United Therapeutics reported revenues of $832.5 million for Q3 2026.

How much did revenues increase year-over-year?

Revenues increased by four percent compared to Q3 2025.

What is the outlook for United Therapeutics?

The company is entering a period of extraordinary growth.

When did United Therapeutics announce its financial results?

The financial results were announced for the quarter ended September 30, 2026.

ShareAdd on Google
Tags: UTHR United Therapeutics financial results Q3 2026 revenue growth Nasdaq: UTHR
Last updated: Nov 4, 2026

Biotech snapshot

Cash runway
$3536M liquidity · $0M/mo burn
Low dilution risk
Lead asset
APD811NDA/BLA
Pulmonary Arterial Hypertension →

Catalyst track record

+27%
best trade around UTHR's most recent catalyst

Peak hindsight return over a 120-day window, across 11 tracked FDA/PDUFA catalysts for UTHR.

See every catalyst's timing & PoA →